Temozolomide — Drug Intelligence | 58 EU Trials

Filter these 58 trials by condition, phase, country and more.

Open in Search →

58 Registered trials

33 Recruiting

14 Completed trials

46 Sponsors

23 Countries

Phase III

Phase II

Phase I/II

Phase III: 16 Phase II/III: 4 Phase II: 21 Phase I/II: 14 Phase I (FiH): 3

Oversight events:

11 temporary halts across 2 trials

View oversight register →

Indications tested

Glioblastoma 11 Neuroblastoma 3 Glioma 3 Glioblastoma multiforme 3 Rhabdomyosarcoma 2 Ewing's sarcoma 2 Medulloblastoma 2 Ewing´s sarcoma metastatic 1 Gastroenteropancreatic neuroendocrine tumour disease 1 Malignant glioma 1 Bladder cancer 1 Colorectal cancer stage II 1

Sponsors using this IMP

The University Of Birmingham 5 Eli Lilly & Co. 3 Institut Gustave Roussy 3 Bristol-Myers Squibb Services Unlimited Company 2 Centre Oscar Lambret 2 Fondazione IRCCS Istituto Nazionale Dei Tumori 2 Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets 2 Oslo University Hospital HF 2 Assistance Publique Hopitaux De Paris 1 AstraZeneca AB 1 Azienda Ospedaliera Universitaria Meyer IRCCS 1 Carthera 1

All trials — page 3

58 total

Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended

2024-510812-64-00 Phase III 5 countries ITM Solucin GmbH
An efficacy and safety study of 2-OHOA in patients with glioblastoma Ended

2024-511542-39-00 Phase II/III 3 countries Laminar Pharmaceuticals S.A.
Phase III randomised trial evaluating chemotherapy early treatment intensification with temozolomide in adults present with a glioblastoma Ended

2022-500451-23-00 Phase III 2 countries Centre Oscar Lambret
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma Halted

2023-508318-41-00 Phase I/II 2 countries Nerviano Medical Sciences S.r.l.
PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS - THE ARETHUSA… Ended

2024-518526-33-01 Phase II 1 country Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year… Ended

2024-512095-35-00 Phase I/II 7 countries Novartis Pharma AG
A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended

2023-506772-28-00 Phase II 4 countries Eli Lilly & Co.
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended

2024-511975-14-00 Phase I/II 5 countries Pfizer Inc.
A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory… Ended

2023-506778-11-00 Phase I/II 1 country Eli Lilly & Co.
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended

2024-518931-12-00 Phase II 5 countries The University Of Birmingham

Showing 49–58 of 58 trials

← All drugs A–Z